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nosocomial organisms is rapidly increasing both for 
Gram-negative and Gram-positive bacteria. However, at 
the moment, Gram-negative bacilli are the greater threat. 
While the prevalence of methicillin-resistant Staphylococ-
cus aureus (MRSA) has plateaued in many countries and 
is even declining in some, the frequency of enterobac-
teriaceae that exhibit high rates of antibiotic resistance 
including broad-spectrum beta-lactamases (extended-spec-
trum beta-lactamase, ESBL) and even carbapenemases is 
rapidly increasing and poses imminent threat for patients 
with infections due to these organisms. For this reason, a 
large number of long-known beta-lactam antibiotics based 
on penicillins or cephalosporins have become ineffective 
in many instances, even when combined with conventional 
inhibitors of beta-lactamases like clavulanic acid or tazo-
bactam [1].
In the past couple of years, pessimism has been spread-
ing with respect to the pipeline of new antimicrobials, and 
many pharmaceutical companies have declared that they 
will not continue to develop new antibacterial compounds. 
At present, the situation has changed positively, and those 
observing preclinical and clinical development strategies 
and activities have reason to be more optimistic. Several 
compounds have been developed in various drug classes 
and against resistant organisms in the whole spectrum of 
multidrug-resistant (MDR) bacteria (Fig. 1).
Compounds against Gram‑positive bacteria
Novel long acting lipoglycopeptides oritavancin 
and dalbavancin
Acute bacterial skin and skin structure infections 
(ABSSSIs) are among the most frequent indications 
Abstract 
Purpose Therapeutic efficacy and safety in infections 
due to multidrug-resistant bacteria can be improved by the 
clinical development of new compounds and devising new 
derivatives of already useful antibiotics. Due to a striking 
global increase in multidrug-resistant Gram-positive but 
even more Gram-negative organisms, new antibiotics are 
urgently needed.
Methods This paper provides a review of novel antibi-
otic compounds which are already in clinical development, 
mainly in phase III clinical trials.
Conclusion Each of these new trials increases the possi-
bility of new antibiotics receiving approval.
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Introduction
New antibiotics are urgently needed due to the alarming 
development of resistance against all antibiotics on the 
market and in clinical use [1, 2]. While this has been the 
case since the detection of antibiotics, recently the gap has 
widened due to the fact that new antibiotic drug classes 
have barely been introduced among others. Moreover, the 
prevalence of difficult to treat resistant and multi-resistant 
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for antimicrobial therapy. The causative agents are usu-
ally Gram-positive bacteria including MRSA for which 
there are a number of treatment options that may be quite 
demanding with respect to application, dosing frequency, 
monitoring requirements, and duration of treatment. With 
the advent of novel lipoglycopeptides (in addition to teico-
planin, which has been available in Europe since 1992 and 
telavancin, which has received FDA approval in 2009), 
characterized by a concentration-dependent bactericidal 
activity and an extended elimination half-life, therapy of 
ABSSSI may become more easily manageable.
Oritavancin has (at least) three distinct mechanisms of 
action, namely inhibition of transglycosylation (like vanco-
mycin), inhibition of transpeptidation (like beta-lactams), 
and disruption of cell membrane integrity (like telavancin) 
[3]. These result in rapid bactericidal activity against a 
number of Gram-positive pathogens. It also has a very long 
terminal half-life of >300 h [4] and demonstrated potent 
bactericidal activity of a single 1200 mg dose in an in 
vitro PK/PD model [5]. It is not metabolized, and there is 
no need for dose adjustment for renal or moderate hepatic 
impairment. This set of characteristics allows for very easy 
administration especially in an outpatient setting. Follow-
ing a phase II study that did not support the daily admin-
istration of oritavancin [6], the recent phase III SOLO I 
trial involving 954 patients in the mITT population dem-
onstrated non-inferiority of a single 1200 mg i.v. dose of 
oritavancin versus 7–10 days of twice daily i.v. vancomy-
cin for ABSSSI with respect to all three efficacy end points 
including cure [7]. This held true for a variety of subgroup 
analyses. While nausea was somewhat more common in the 
oritavancin group (11 vs. 8.9 %), there was no statistically 
significant difference with respect to safety or tolerability 
in general. Oritavancin therefore has the potential to be 
used as single-shot treatment for ABSSSIs virtually elimi-
nating adherence issues. As stated for the SOLO I as well 
as the SOLO II trial, the prolonged half-life of oritavancin 
was not associated with any safety issues including the 
60 day follow-up period [7].
Dalbavancin is another semisynthetic lipoglycopeptide 
and has been evaluated for skin and soft tissue/skin struc-
ture infections [8, 9] as well as catheter-associated blood 
stream infections [10] already since the early 2000s. It has 
been shown to have only a minor impact on the gut flora 
[11]. Its terminal half-life of about 2 weeks [12] also allows 
for extended dosing intervals. Recently, the twin-phase III 
DISCOVER-1 and DISCOVER-2 trials for ABSSSI with 
1312 patients in the pooled analysis were published. They 
demonstrated non-inferiority of two single doses of dalba-
vancin given 1 week apart compared to a standard twice-
daily treatment regimen of i.v. vancomycin followed by an 
optional switch to p.o. linezolid for a total of 10–14 days 
[13]. This was true for both the primary end point of early 
clinical success and end of treatment success, independent 
of causative pathogen or comorbidity. Non-inferiority of a 
two-dose regimen is even more remarkable when consider-
ing that about half the patients met the criteria for systemic 
inflammatory response syndrome (SIRS). Dalbavancin had 
a favorable safety profile with both fewer adverse events 
and fewer patients experiencing adverse events. Nausea 
was noted to be the most frequent adverse event in the dal-
bavancin group occurring in 2.5 % of patients. Notably, 
the use of dalbavancin was associated with a significantly 
lower mortality (0.2 vs. 1.1 %). This has led to the FDA 
approval of dalbavancin for ABSSSI caused by S. aureus 
and S. pyogenes in May 2014.
Fig. 1  Schematic antibiotic action: new compounds in an overview
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Tedizolid
Tedizolid phosphate is a new oxazolidinone compound. Its 
mechanism of action is similar to that of linezolid, which 
was the first drug in this class: It acts by inhibition of the 
ribosomal protein synthesis of bacteria. The exact mecha-
nism of blockade is located at the 50S subunit of the bacte-
rial ribosome, which is directly targeted by oxazolidinones 
in a way that inhibits binding of the tRNA by a conforma-
tional change in the binding moiety. Thereby, the protein 
synthesis chain is terminated [14, 15]. The active com-
pound of tedizolid emerges by cleavage of the phosphate 
moiety of the prodrug. Tedizolid is active against Gram-
positive bacteria, including MRSA. Vancomycin-resistant 
organisms and even linezolid-resistant MRSA have been 
found to be susceptible to the new drug [15–17].
Substantial pharmacological data on tedizolid show its 
suitability for clinical use as an antibiotic. Pooled analyses 
of intravenous and oral application have shown correlations 
of drug levels with clinical success. The absolute bioavail-
ability of tedizolid is higher than 80 % which is compara-
ble to linezolid [14, 17–20]. More positive pharmacologi-
cal data show a lower interaction potential of tedizolid as 
compared to linezolid, e.g., no interaction with inhibitors of 
the monoamino-oxidase (MAO-inhibitors). The long half-
life of tedizolid in combination with a high bioavailability 
offers the realistic rationale for once daily administration. 
With a 10- to 12-h half-life, drug levels of tedizolid above 
the MIC can still be accomplished at the end of a 24-h dose 
interval. About 80 % of the drug is eliminated via the gut 
and about 20 % renally.
Because the compound has good tissue penetration, one 
clinical area of use is ABSSSI.
The two-phase III ESTABLISH 1 and ESTABLISH 2 
trials showed non-inferiority compared to linezolid, leading 
to approval of the new drug by the FDA in June 2014 [15, 
16]. In ESTABLISH 2, a total of 666 patients with ABSSSI 
were recruited in nine countries with 58 participating treat-
ment sites. A 1:1 randomization allocated patients in a dou-
ble-blind manner to either tedizolid 200 mg intravenously 
followed by oral medication over 6 days or to linezolid at 
a dose of 600 mg by mouth twice daily over a period of 
10 days. Stepdown from intravenous to oral medication 
could take place if the criteria of early clinical response 
were fulfilled. Early clinical response was defined as a 
reduction in the inflamed area by at least 20 % in the first 
3 days. This criterion was reached roughly with equal fre-
quency in both trial arms: In the tedizolid arm 85 % and 
in the linezolid arm 83 % of all patients had early clini-
cal response. Regarding adverse events and safety issues, 
there was a significantly lower incidence of gastrointestinal 
adverse reactions in the tedizolid group (16 vs. 23 %) [16, 
17, 21].
In addition to clinical efficacy data, there have been 
studies investigating pharmacological issues in special 
populations: Patients with renal failure and with hepatic 
insufficiency have been subject to pharmacokinetic sam-
pling. The results show that no dose adjustment is neces-
sary in patients with chronic renal failure with and without 
hemodialysis treatment. Only 10 % of the antibiotics were 
removed by dialysis. In patients with hepatic impairment, 
a moderate increase in drug levels in the range of 22–34 % 
was observed [19].
Drugs against Gram‑negative bacteria 
and broad‑spectrum antibiotics
BAL30072
BAL30072 is a monosulfactam antibiotic, which exhibits 
activity against carbapenem-resistant Enterobacteriaceae 
and non-fermenters [22–24]. The chemical structure of 
BAL30072 is related to that of aztreonam. BAL 30072 
belongs to the group of beta-lactam antibiotic and inhibits 
bacterial cell wall synthesis. In vitro tests of combinations 
with beta-lactamase inhibitors such as clavulanate and BAL 
29880 were described. The combination of BAL30072 with 
BAL29880 or clavulanate resulted in susceptibility rates of 
more than 90 % of all isolates tested in vitro. At 4 mg/l, 
BAL30072 showed activity against all OprD-deficient 
Pseudomonas aeruginosa [23–25]. Also, most Acinetobac-
ter baumannii strains expressing OXA or NMD carbapen-
emases were susceptible to BAL30072 [25].
In an in vitro study, the activity of BAL30072 and other 
standard antibiotics against meropenem-resistant A. bau-
mannii was evaluated, and a MIC90 of ≥64 was shown 
[23]. Burkholderia pseudomallei, the pathogen causing 
melioidosis, displays constitutive resistance toward a range 
of antimicrobials. Thus, treatment is difficult. In a study 
with its laboratory strains (1026b, 1710b) and several 
strains isolated in Thailand, more than 93 % of the isolates 
were susceptible to BAL30072 with minimal inhibitory 
concentrations (MICs) in the range of 0.004–0.016 µg/ml 
[24].
Compared to ceftazidim, meropenem, and imipenem, 
BAL30072 showed markedly higher activity with a MIC90 
of 0.016 µg/ml. At the time of writing, BAL30072 is being 
investigated in phase I clinical studies [26, 27].
Ceftolozane
Ceftolozane combined with tazobactam is being inves-
tigated for complicated urinary tract infections (cUTIs), 
complicated intra-abdominal infections (cIAIs) and 
ventilator-associated pneumonia (VAP). It is a novel 
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cephalosporin with a structure similar to ceftazidim. It 
exerts activity against Pseudomonas (including ceftazidim-
resistant P. aeruginosa) and also against bacteria-producing 
beta-lactamases such as TEM-1 (Temoneira: In 1965, this 
beta-lactamase was found in a patient called Temoneira) 
and SHV-1 (SHV = sulfhydryl variable) [28–30]. Ceftolo-
zane shows no activity against bacteria-producing ESBL 
and carbapenemases. However, in combination with tazo-
bactam, it is active against most of the bacteria-producing 
ESBL and against some anaerobes. The mean plasma half-
life is 2.3 h, and protein binding of ceftolozane is low at 
approximately 20 %. Two-phase II studies of ceftolozane 
with tazobactam in urinary tract infections and abdominal 
infections have been completed. One-phase III study has 
been terminated since a larger phase III study in VAP was 
planned in comparison with meropenem which has already 
started to enroll. The FDA approved ceftolozane/tazobac-
tam to treat adults cIAI and cUTI in December 2014, and 
approval in Europe is expected for the end of 2015 [31, 32]. 
So far, the clinical and microbiological activity appears 
comparable to imipenem and ceftazidim: For P. aerugi-
nosa, the MIC was 0.5 mg/l for ceftolozane, 1 mg/l for cef-
tazidim, and 0.5 mg/l for imipenem [33–35].
Delafloxacin (fluoroquinolone)
Quinolones are inhibitors of the bacterial DNA gyrase and 
topoisomerases (mostly topoisomerase IV). There are four 
generations of well-characterized quinolones which could 
be further developed, e.g., toward additional MRSA activity 
or better tissue penetration in neutral or acidic environments.
Delafloxacin is a promising investigational fluoroqui-
nolone. In comparison with others, the substituent on posi-
tion 7 of the quinoline ring system is not protonatable which 
results in a pKa shift. In contrast, other fluorquinolones are 
zwitterionic and therefore neutrally charged only at a physi-
ological pH. Neutral charge is required for membrane pen-
etration. Delafloxacin also permeates membranes at lower 
pH such as found in inflamed tissue [36, 37]. In inflamma-
tory tissue of soft tissue infections, abdominal infections, or 
urinary tract infections, pH levels are mildly acidic (about 
5.5–6). Under these conditions, e.g., 90 % of moxifloxacin 
is in a cationic state and therefore unable to permeate bac-
terial membranes. In contrast, delafloxacin is uncharged at 
this pH resulting in high cellular uptake [36]. Delafloxacin 
was already investigated in phase II studies for community-
acquired pneumonia (CAP) and ABSSSI. The results were 
very promising so that phase III studies were initiated [38].
Omadacycline and eravacycline
Tetracyclines are bactericidal and inhibit protein synthe-
sis by binding to the 30S subunit of microbial ribosomes. 
While omadacycline and eravacycline do not have advan-
tages over tigecyclin in terms of their microbiological 
activity, both drugs are orally bioavailable and therefore 
interesting for further development [15].
Currently, omadacycline is being compared to linezolid 
in a phase III study in ABSSSI. It is administered paren-
terally in the initial phase. After clinical recovery, a switch 
to oral administration is possible. Omadacycline doses are 
100 mg for intravenous and 150 mg for oral application 
[38].
Phase III studies of eravacycline are conducted with the 
antibiotic comparators levofloxacin or ertapenem in urinary 
tract infections and cIAI. Eravacyclin is administered par-
enterally every 12 h in cIAI.
Solithromycin (ketolide)
Solithromycin is a ketolide and derived from the macrolide 
erythromycin. The molecular mode of action is similar to 
telithromycin. It inhibits protein synthesis by binding ribo-
somal subunits. Microbiologically, the drug differs from 
macrolides due to additional MRSA activity and activity to 
resistant Streptococci.
Solithromycin is being investigated in clinical studies 
for CAP [39] and for gonococcal urethritis and compared 
with quinolones (levofloxacin and moxifloxacin) and the 
combination of ceftriaxone and azithromycin [38]. In vitro 
data and the existing clinical data suggest a lower risk of 
hepatotoxicity than for telithromycin [40].
Novel beta-lactamase inhibitors
The beta-lactamase inhibitors currently available for 
clinical application, i.e., sulbactam, clavulanate and tazo-
bactam, inhibit beta-lactamases of the molecular class 
A reflecting the original TEM and SHV genes. Recently, 
other beta-lactamases are emerging which contribute to the 
increasing resistance especially of Gram-negative bacilli. 
Among those are oxacillinases [belonging to class D; 
OXA-1/10 (OXA = oxacillin hydrolyzing capabilities)], 
cephalosporinases [belonging to class C; AmpC (ampicil-
lin class C BLI)], CMY-2 (cephamycin-BLI no. 2), FOX-1 
(cefoxitin-BLI) and the metallo-beta-lactamases [belong-
ing to class B; IMP-1 (imipenem-BLI), VIM-1/2 (Verona 
integron-encoded metallo-beta-lactamase), NDM-1 (New 
Delhi metallo-beta-lactamase), CphA (metallo-beta-lac-
tamase from Aeromonas hydrophila), and Sfh-1 (beta-
lactamase from Serratia fonticola)]. Novel beta-lactamase 
inhibitors (e.g., diazabicyclooctane-related substances) 
are able to also inhibit enzymes of these other groups to 
a various degree. They therefore contribute substantially to 
meet the increasing need for new drugs against ESBL or 
Klebsiella pneumonia carbapenemases (KPCs)-producing 
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bacilli. Important representatives of these new beta-lacta-
mase inhibitors are avibactam and MK-7655.
Avibactam
Avibactam belongs to the group of diazabicyclooctanes 
[22, 41]. It inhibits nearly all class A and class C (AmpC) 
beta-lactamases. Due to its activity against various beta-
lactamases, it is suitable for clinical testing in the setting 
of severe infections with multi-resistant Gram-negative 
bacteria. It was combined with either ceftazidime or cef-
taroline. In vitro, ceftazidime/avibactam is active against 
multi-resistant enterobacteriaceae [e.g., bacilli with induc-
ible or derepressed AmpC-beta-lactamases, class A beta-
lactamases, carbapenemases belonging to class A (KPC) 
and class D (OXA-48)]. However, metallo-beta-lactamase 
producers were resistant toward avibactam [42].
The clinical efficacy and the safety of ceftazidime/avi-
bactam are being tested in phase III clinical trials with 
different clinical indications. Among these are urosepsis, 
severe urinary tract infections, and intra-abdominal infec-
tions. In phase II clinical trials, it was shown that the effi-
cacy of ceftazidime/avibactam was non-inferior to the car-
bapenem control group [22, 43].
In the two-phase III RECLAIM-1 and RECLAIM-2 tri-
als, intravenous ceftazidime/avibactam plus metronidazole 
was compared to meropenem for cIAI. Ceftazidime/avibac-
tam (2000 mg/500 mg) was infused over 2 h. Meropenem 
(1000 mg) was given over 30 min. The combination ceftazi-
dime/avibactam/metronidazole met its primary end point of 
non-inferiority as shown by preliminary results [43].
Mk-7655
MK-7655 is a novel beta-lactamase inhibitor under clini-
cal development. In vitro, it was tested against a KPC-2 
carbapenemase-producing Klebsiella pneumoniae (isolate 
KP6339) and also against P. aeruginosa isolates lacking the 
OprD porin and overexpressing AmpC (isolates PA24226, 
PA24227, and PA24228). Synergism of MK-7655 in com-
bination with imipenem was shown [44]. At the moment, 
a phase II study for severe urinary tract infections is being 
conducted. This study aims to proof that 125 or 250 mg 
MK-7655 in combination with imipenem is non-inferior to 
imipenem only [38].
RPX7009 and AAI101
RPX7009 is a cyclic, boric acid-based beta-lactamase 
inhibitor active against serine-carbapenemases. It was 
given to 56 individuals in a dosage between 250 and 
2000 mg as a single dose or up to 7 days as 3-h infusion. 
The substance is mainly eliminated via the renal pathway 
and did not accumulate. Analysis of tolerability showed no 
significant difference to placebo. Severe adverse events did 
not occur [45].
AAI101 is a hybrid ionic beta-lactamase inhibitor with 
broad activity against ESBL. Efficacy was shown in combi-
nation with ceftriaxone, cefepime, or piperacillin in animal 
models and was compared to combinations with tazobac-
tam. Clinical efficacy was defined as lethality of an intra-
peritoneal application of ESBL Gram-negative bacteria, 
and efficacy was significantly higher for all three combina-
tions with AAI101 than for the control groups [46].
Cadazolid, a novel substance for treating C. difficile
Cadazolid is a novel antimicrobial agent with structural 
analogy to both oxazolidinones and fluoroquinolones. It has 
high and relatively selective efficacy against C. difficile. Its 
mechanism of action is inhibition of protein biosynthesis, 
which also leads to a highly effective suppression of toxin 
production. In addition, it strongly inhibits spore forma-
tion [47]. According to microbiological in vitro and animal 
models, one advantage of cadazolid is its relatively weak 
impact on the intestinal microbiota [48]. Also, there is no 
relevant intestinal absorption, leading to high intraluminal 
concentrations and a low systemic impact [49]. Cadazolid 
was tested in a multicentric, randomized, and double-blind 
phase II trial in patients with C. difficile-associated diar-
rhea (CDAD) using doses ranging from 250 to 1000 mg 
per day over 10 days [50]. Standard dose oral vancomycin 
was used as comparator. A total of 84 patients with CDAD 
were included, and the study was completed in December 
of 2012. The efficacy of all dosages of cadazolid was simi-
lar or better compared to vancomycin with respect to all 
clinical end points, specifically cure rate and frequency of 
relapses. At the same time, the drug was well tolerated. Cur-
rently, a dosage of 250 mg bid is being tested versus vanco-
mycin 125 mg qid in the large phase III IMPACT trial [51].
Conclusion
In conclusion, there are several promising compounds on 
their way through clinical development which will broaden 
the possibilities for treatment of MDR bacteria, especially 
against MRSA and Gram-negative ESBL bacteria. But the 
evolution of resistance mechanisms will not stop with the 
introduction of the new drugs. Therefore, the race must 
continue, and drugs with new mechanisms of action need to 
be investigated and tested for clinical use. Equally impor-
tant, however, is the reduction in new infections and the 
counteraction of rising rates of antibiotic resistance with 
infection control mechanisms.
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